Published • loading... • Updated
More People Now Use GLP-1s for Weight Loss than for Other Health Conditions, Research Finds
The committee says the rollout reaches only 6% of eligible patients and urges wider access, better data-sharing and stronger action against the black market.
- On Friday, the Health and Social Care Committee criticized the NHS rollout of Mounjaro, warning that current plans are 'unambitious' and will reach only a 'woefully small number of people' eligible for the weight-loss drug.
- Data indicates only around 6% of eligible patients will receive Mounjaro over three years, as the NHS restricts access to those with a BMI of more than 35 and four serious health conditions.
- A 'two-tier system' for access risks driving patients to unregulated black market sources for GLP-1s, committee members warned, as those unable to access NHS treatment face significant private costs.
- To improve access, MPs recommended doubling bariatric surgery—a 'cost-effective underutilised treatment for obesity'—and leveraging approved digital providers to prescribe and monitor patients at scale, reducing the burden on GPs.
- Committee chairwoman Layla Moran argued that treating obesity as a chronic condition rather than a lifestyle issue could 'save the NHS billions in the long-term,' urging officials to prioritize improvements to obesity care.
Insights by Ground AI
6 Articles
6 Articles
NHS Mounjaro rollout plan deemed ‘unambitious’ by MPs
Current plans for rolling out weight-loss drug Mounjaro on the NHS “are unambitious” and reach a “woefully small number of people”, MPs have said. Only around 6% of eligible people will get or currently receive Mounjaro (a GLP-1 weight loss drug) on the NHS in its first three years, with [...] The post NHS Mounjaro rollout plan deemed ‘unambitious’ by MPs first appeared on Rother Radio.
Coverage Details
Total News Sources6
Leaning Left0Leaning Right1Center2Last UpdatedBias Distribution67% Center
Bias Distribution
- 67% of the sources are Center
67% Center
C 67%
R 33%
Factuality
To view factuality data please Upgrade to Premium
